BioCryst Pharmaceuticals (BCRX) Rating Lowered to Strong Sell at ValuEngine

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Wednesday.

A number of other brokerages also recently weighed in on BCRX. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 8th. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Tuesday, January 2nd. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. Finally, Barclays initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 price objective for the company. Two research analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $8.63.

BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up $0.12 on Wednesday, hitting $5.11. 1,360,983 shares of the stock traded hands, compared to its average volume of 1,520,000. The company has a market cap of $502.85, a P/E ratio of -7.98 and a beta of 2.80. BioCryst Pharmaceuticals has a one year low of $3.95 and a one year high of $9.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53.

Several large investors have recently made changes to their positions in the stock. BlackRock Inc. grew its position in shares of BioCryst Pharmaceuticals by 15.0% during the 4th quarter. BlackRock Inc. now owns 7,614,280 shares of the biotechnology company’s stock valued at $37,386,000 after buying an additional 993,100 shares during the last quarter. Vanguard Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 19.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock valued at $33,404,000 after buying an additional 996,052 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at about $23,762,000. State Street Corp grew its position in shares of BioCryst Pharmaceuticals by 72.0% during the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock valued at $21,736,000 after buying an additional 1,636,909 shares during the last quarter. Finally, RTW Investments LP boosted its stake in BioCryst Pharmaceuticals by 1.4% during the 4th quarter. RTW Investments LP now owns 3,372,674 shares of the biotechnology company’s stock valued at $16,560,000 after purchasing an additional 47,969 shares during the period. 84.80% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/biocryst-pharmaceuticals-bcrx-rating-lowered-to-strong-sell-at-valuengine.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply